Immunitybio Inc ((IBRX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ImmunityBio Inc. is conducting a Phase 2 study titled Open-label Phase 2 Study of N-803 and PD-L1 t-haNK Combined With Bevacizumab in Subjects With Recurrent or Progressive Glioblastoma. The study aims to evaluate the safety and efficacy of combining N-803 and PD-L1 t-haNK with Bevacizumab for treating recurrent or progressive glioblastoma, a significant challenge in oncology due to its aggressive nature.
The intervention involves a combination therapy where participants receive N-803 subcutaneously, PD-L1 t-haNK intravenously, and Bevacizumab intravenously. This treatment is designed to enhance the immune response against tumor cells and inhibit tumor growth.
The study follows a single-group, open-label design with no masking, focusing on treatment as the primary purpose. Participants undergo 28-day treatment cycles, with a maximum of 19 cycles over 76 weeks, unless treatment is discontinued due to toxicity or disease progression.
The study began on August 7, 2024, with the latest update submitted on July 30, 2025. These dates are crucial as they mark the study’s progression and the timeline for potential data availability.
This clinical update could positively influence ImmunityBio’s stock performance by showcasing its commitment to innovative cancer therapies. Investors might view this as a promising development in the competitive oncology market, potentially impacting investor sentiment favorably.
The study is ongoing, with further details available on the ClinicalTrials portal.